Sulfonamide compounds and uses as TNAP inhibitors
Described herein are compounds that modulate the activity of TNAP. In some embodiments, the compounds described herein inhibit TNAP. In certain embodiments, the compounds described herein are useful in the treatment of conditions associated with hyper-mineralization.
1. A compound of Formula I, or a pharmaceutically acceptable salt, polymorph, solvate, tautomer, or N-oxide thereof:
wherein:
Y 1 is a bond, and Y 2 is —N(R 6 )—;
L 1 and L 2 are each a bond;
X 1 is ═N— or ═C(R 2 )—;
X 2 is ═N— or ═C(R 3 )—;
R 1 and R 4 are independently selected from the group consisting of —F, —Cl, —Br, —CN, —C(O)—N(R 7 )—R 8 , —C(O)—O—R 9 , —OMe, —OCF 3 , optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl;
R 2 , R 3 , and R 5 are hydrogen;
R 6 is hydrogen;
R 7 and R 8 are independently hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted phenyl, or R 7 and R 8 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino;
R 9 is selected from the group consisting of hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted phenyl; and
A is —C(O)—N(R 7 )—R 8 , or —C(O)—O—R 9 ,
or A is an optionally substituted phenyl or optionally substituted 5- or 6-membered heteroaryl, wherein A is selected from:
R 12 and R 13 are independently selected from the group consisting of hydrogen, halogen, —CN, —OH, —C(O)—O—R 19 , optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl;
R 19 is selected from the group consisting of hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted phenyl; and
R 15 is hydrogen or optionally substituted alkyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
Y 1 is a bond and Y 2 is —N(R 6 )—;
X 2 is ═C(R 3 )—;
L 1 is a bond;
L 2 is a bond; and
R 6 is hydrogen as shown in Formula Ie:
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein X 1 is ═C(R 2 )—.
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is optionally substituted phenyl, optionally substituted 5- or 6-membered heteroaryl, —C(O)—N(R 7 )—R 8 , or —C(O)—O—R 9 .
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 and R 4 are independently selected from the group consisting of F, —Cl, —Br, —CN, —OMe, and —OCF 3 .
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein A is optionally substituted phenyl or optionally substituted 5- or 6-membered heteroaryl, wherein A is selected from:
R 12 and R 13 are independently selected from the group consisting of hydrogen, halogen, —CN, —OH, —C(O)—O—R 19 , optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted alkoxy, haloalkyl, haloalkoxy, optionally substituted phenyl, and optionally substituted 5- or 6-membered heteroaryl;
R 19 is selected from the group consisting of hydrogen, optionally substituted alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, and optionally substituted phenyl; and
R 15 is hydrogen or optionally substituted alkyl.
7. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein:
A is
wherein R 12 and R 13 are independently selected from the group consisting of hydrogen, —F, —CN, —OH, —OMe, and —C(O)—O-Me; or
A is —C(O)—O—R 9 ; or
A is —C(O)—N(R 7 )—R 8 .
8. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein A is —C(O)—O—R 9 , wherein R 9 is selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, and optionally substituted phenyl.
9. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein A is —C(O)—N(R 7 )—R 8 , wherein R 7 and R 8 together with the nitrogen atom to which they are attached form an optionally substituted heterocycloamino.
10. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein the optionally substituted heterocycloamino is an optionally substituted pyrrolidine, an optionally substituted piperidine, an optionally substituted morpholine, or an optionally substituted piperazine.
11. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein A is —C(O)—N(R 7 )—R 8 , wherein R 7 is hydrogen and R 8 is optionally substituted alkyl, optionally substituted cycloalkyl, or optionally substituted phenyl.
12. The compound of claim 7 , or a pharmaceutically acceptable salt thereof, wherein A is —C(O)—N(R 7 )—R 8 , wherein R 7 and R 8 are hydrogen.
13. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
14. A compound that has one of the following structures:
or a pharmaceutically acceptable salt thereof.